Merck Presents Results of Islatravir + Doravirine in P-IIb Clinical Trial for the Treatment of HIV-1 at EACS 2021
Shots:
- The P-IIb dose-ranging study evaluates the antiretroviral activity, tolerability & safety of islatravir (0.25/0.75/2.25mg) + doravirine vs DOR/3TC/TDF in a ratio (1:1:1:1) in adults with HIV-1
- The results showed that islatravir + doravirine continued to maintain viral suppression @144wks.; 72.2% of the combined groups had HIV-RNA levels <50 copies/mL similar to 77.4% of DOR/3TC/TDF group.; treatment discontinuations due to drug-related AEs (2.2% & 3.2%) before 48wks. The results were consistent with the 96wks. results in 0.75mg dose group
- Islatravir is currently being evaluated in multiple dosing regimens for HIV-1 as monothx. or in combination with other antiretroviral agents
Ref: Merck | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com